The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Aztreonam lysine (Cayston®) has been accepted for restricted as suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older. Use is limited to cases where inhaled colistimethate sodium and inhaled tobramycin are not tolerated or providing an unsatisfactory therapeutic benefit. It is also contingent on the continued availability of a Patient Access Scheme (PAS) that improves the cost effectiveness.
Brimonidine (Mirvaso®) has been accepted for restricted use in the symptomatic treatment of facial erythema of rosacea in adult patients. The restriction limits use to patients with moderate to severe persistent facial erythema associated with rosacea.
Canagliflozin plus metformin (Vokanamet®) has been accepted for restricted use in type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control. The restriction limits use of this product to patients where combination of canagliflozin and metformin is an appropriate choice of therapy.
Olodaterol (Striverdi®) has been accepted for use as maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« MTRAC Reviews - December 2014||Key therapeutic topics 2015 »|